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Background: Mutations in the gene encoding parkin, a neuroprotective protein with dual functions as an E3
ubiquitin ligase and transcriptional repressor of p53, are linked to familial forms of Parkinson’s disease (PD). We
hypothesized that oxidative posttranslational modification of parkin by environmental toxins may contribute to
sporadic PD.
Results: We first demonstrated that S-nitrosylation of parkin decreased its activity as a repressor of p53 gene
expression, leading to upregulation of p53. Chromatin immunoprecipitation as well as gel-shift assays showed that
parkin bound to the p53 promoter, and this binding was inhibited by S-nitrosylation of parkin. Additionally,
nitrosative stress induced apoptosis in cells expressing parkin, and this death was, at least in part, dependent upon
p53. In primary mesencephalic cultures, pesticide-induced apoptosis was prevented by inhibition of nitric oxide
synthase (NOS). In a mouse model of pesticide-induced PD, both S-nitrosylated (SNO-)parkin and p53 protein levels
were increased, while administration of a NOS inhibitor mitigated neuronal death in these mice. Moreover, the
levels of SNO-parkin and p53 were simultaneously elevated in postmortem human PD brain compared to controls.
Conclusions: Taken together, our data indicate that S-nitrosylation of parkin, leading to p53-mediated neuronal cell
death, contributes to the pathophysiology of sporadic PD.
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Characterized by motor impairment and, with time, cog-
nitive deficits, Parkinson’s disease (PD) affects ~1% of
people over the age of 65 [1]. Histopathological features
include loss of dopaminergic neurons, predominantly in
the substantia nigra pars compacta, often accompanied
by intracellular inclusions called Lewy bodies [2,3]. Ra-
ther than associated with a single gene mutation, more
than 95% of PD cases are sporadic in nature, in some
cases epidemiologically linked to pesticide exposure
[4,5]. Although there are symptomatic treatments for PD* Correspondence: slipton@sanfordburnham.org
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reproduction in any medium, provided the orpatients, currently there is no effective therapy to pre-
vent or cure this malady.
Mutations in the parkin gene have been associated with
autosomal recessive juvenile PD and rare adult cases [6-9].
Parkin encodes an E3 ubiquitin ligase [9,10], and disrup-
tion in parkin-mediated protein ubiquitination may con-
tribute in part to neuronal cell death [11-16], although
other neuroprotective actions of parkin have also been
reported [17,18]. In this regard, a novel role of parkin as a
transcriptional repressor of p53 was recently demon-
strated [19,20].
Processes leading to progression of sporadic PD re-
main largely unknown. Several environmental stressors,
including oxidative and nitrosative stress, have been epi-
demiologically linked to sporadic PD [21,22]. PD-linked
environmental stressors may cause alterations in parkin
solubility, promoting its aggregation and compromisingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nitrosative stress can cause posttranslational modifica-
tions on parkin (sulfonation and S-nitrosylation, respect-
ively) to disrupt its E3 ligase activity [24-26].
In the present study, we demonstrate that S-nitrosylation
of parkin also decreased its activity as a repressor of p53
gene expression, and led to an upregulation of p53 mRNA
and protein. Chromatin immunoprecipitation as well as
gel-shift assays showed that parkin bound to the p53 pro-
moter, and this binding was inhibited by the S-nitrosylation
of parkin. Additionally, nitrosative stress, induced by pesti-
cides that have been reported to be epidemiologically linked
to PD, induced SNO-parkin and cell death in a p53-
dependent manner in both cell-based and animal models.
Administration of a NOS inhibitor mitigated the increase
in SNO-parkin and p53 as well as neuronal cell death. Fi-
nally, in postmortem human PD brain, the levels of SNO-
parkin and p53 were increased in a correlative manner.
Taken together, our data indicate that S-nitrosylation of
parkin contributes to p53-mediated neuronal cell death, in
part underlying the pathophysiology of sporadic PD.
Results
Parkin is a negative regulator of p53
Parkin has been reported to act as a transcriptional repres-
sor of the p53 gene [20]. Initially, we confirmed this result
by transiently expressing parkin in human embryonic kid-
ney (HEK)-293 or human neuroblastoma SH-SY5Y cells
and monitoring p53 promoter activity using a luciferase
reporter assay. We found that parkin expression decreasedFigure 1 Parkin functions as a repressor of p53 transcription and pro
HEK-293 and SH-SY5Y cells transiently transfected with parkin or the contro
expressing parkin (P-SY5Y). D-E, Western blot analyses of parkin, p53 and a
Quantification of p53 signal (right panels) was made relative to actin and e
12 (B), 18 (C), 3 (D) and 9 (E); * p < 0.01.p53 reporter gene activity in HEK-293 (Figure 1A) and
SH-SY5Y (Figure 1B) cells by 16% and 22%, respectively,
compared to vector-transfected control cells. Additionally,
we measured p53-promoter activity in an SH-SY5Y neuro-
blastoma cell line stably overexpressing parkin (Parkin-
SY5Y cells), and found that p53 promoter activity was
decreased 68% compared to the control (Figure 1C). For
further analysis, we quantified the effect of parkin
overexpression on p53 protein levels by immunoblotting.
In cells transiently overexpressing parkin, p53 protein
levels were decreased by 21% (Figure 1D), and in cells sta-
bly expressing parkin, p53 decreased by 91% (Figure 1E).
These experiments confirmed that exogenously expressed
parkin acts as a transcriptional repressor of p53 in these
experimental systems.
S-Nitrosylation of parkin reduces its ability to repress p53
gene expression
We next asked whether S-nitrosylation of parkin affects
its ability to repress p53 transcription. We initially used
the neuroblastoma SH-SY5Y cells because the endogen-
ous level of parkin expression is very low in this cell line
(see Figure 1D), allowing us to easily identify the effect
of parkin overexpression on activity. However, since par-
kin is not detectable in SH-SY5Y cells, this cell type can-
not be used to assess the role of endogenous parkin in
cell death occurring in Parkinson’s disease.
We transiently transfected SH-SY5Y neuroblastoma
cells with control pcDNA1 (pcDNA) or parkin-expression
vector, together with a vector encoding the p53-reporter.tein levels. A-B, p53 promoter activity measured by luciferase assay in
l vector pcDNA. C, p53 promoter activity in SH-SY5Y cell line stably
ctin in SH-SY5Y cells transiently (D) or stably (E) expressing parkin.
xpressed in arbitrary units (a.u.). All values are mean + SEM, n = 6 (A),
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lenged with 200 μM of the NO donor S-nitroso-glutathione
(GSNO) for 6 hours. Using the biotin-switch technique, we
found that parkin was S-nitrosylated under this condition
(Figure 2B) [24,26].
Both with the pcDNA and parkin-expression vector, the
cells exhibited higher levels of p53 promoter activity after
GSNO exposure (Figure 2A), and the increase in p53 pro-
moter activity was greater in cells expressing parkin than
in control cells transfected with pcDNA. These data sug-
gest that S-nitrosylation of parkin reduces the transcrip-
tional repressor activity on the p53 gene. Furthermore, we
performed immunoblotting and quantified the levels of
p53 proteins in SH-SY5Y cells transfected with parkin-
expression vector and subsequently exposed to GSNO.
GSNO induced a significant increase in the p53 protein
level in parkin-transfected SH-SY5Y neuroblastoma
cells (Figure 2B). In summary, exogenous NO attenu-
ated parkin-mediated repression of p53 transcription in
SH-SY5Y cells.
S-Nitrosylation alters nuclear localization of parkin and
reduces its ability to bind to the p53 promoter
For transcriptional repressor activity, parkin must be lo-
cated in the nucleus in order to bind to DNA. It is thus
possible that S-nitrosylation attenuates parkin function
by altering nuclear localization of the protein. To test
this notion, we examined the localization of parkin in
cells exposed to S-nitrosocysteine (SNOC). We transi-
ently transfected SH-SY5Y cells with myc-tagged parkin
and exposed them to 200 μM SNOC (or NO-dissipated
control). Six hours later the cells were fixed, immu-
nostained with anti-myc antibody, and stained with
Hoechst. We found that parkin was localized in both the
nucleus and cytoplasm in control-treated cells, while
parkin was preferentially localized in the cytoplasm in
cells exposed to SNOC (Figure 3A). These data indicateFigure 2 Effect of NO on p53 transcription and protein levels in parki
transfected with the control (pcDNA) or Parkin-expression plasmid. The tran
or the control compound GSH. Values are expressed as a percentage of th
parkin, p53 and actin by western blot (left panel) in cells transiently transfec
Quantification of p53 levels (right panel) was made relative to actin and exp
* p < 0.01, ** p < 0.05.that S-nitrosylation of parkin leads to its exclusion from
cell nuclei.
Using chromatin immunoprecipitation (ChIP), we stud-
ied the physical interaction between parkin protein
and the p53 promoter sequence in SH-SY5Y cells. In cells
overexpressing parkin compared to mock-transfected cells,
we observed a significant increase in the level of parkin
binding to the p53 promoter (Figure 3B). However,
when we exposed these cells to 200 μM GSNO, we
could no longer detect a physical interaction between
the two proteins (Figure 3B). These analyses suggest
that S-nitrosylation of parkin attenuates its ability to
bind to the p53 promoter.
We also performed electrophoretic mobility shift as-
says (EMSAs) to monitor the physical interaction be-
tween parkin protein and the p53 promoter sequence
in vitro. With increasing concentrations of recombinant
parkin protein, we found an increase in the amount of
shifted double-stranded oligonucleotide probe (Pp53)
encoding the human p53 promoter (Figure 3C; left
panels). Pre-incubation of parkin protein with 200 μM
‘old’ SNOC for 10 minutes prior to the binding assay did
not affect parkin-Pp53 interaction, while pre-incubation
with 200 μM SNOC significantly reduced the amount of
mobility-shifted p53 promoter probe (47% relative to old
SNOC; Figure 3C). These data indicate that S-nitro-
sylation of parkin attenuates its ability to bind to the p53
promoter region.
NO induces p53-dependent cell death in parkin-
overexpressing cells
We next asked whether S-nitrosylation of parkin con-
tributes to p53-mediated neuronal cell death. To this
end, we overexpressed parkin in SH-SY5Y cells and ex-
posed them to a high concentration of the NO donor
SNOC. In order to evaluate the involvement of p53 in
this process, we performed gene silencing using a shortn-overexpressing SH-SY5Y cells. A, p53 promoter activity in cells
sfected cells were subsequently exposed to 200 μM NO donor GSNO
e control (pcDNA-transfected GSH-treated cells). B, Protein levels of
ted with parkin or pcDNA, and exposed to 200 μM GSNO or GSH.
ressed in arbitrary units (a.u.). Values are mean + SEM, n = 3;
Figure 3 Effect of NO on subcellular localization of parkin and its physical interaction with p53 promoter (Pp53). A, Histological images
of SH-SY5Y cells transiently transfected with myc-tagged parkin and exposed to 200 μM old or fresh SNOC. Cells were probed with anti-myc
antibody (green) and Hoechst stain (blue). Quantification of the intensity ratio of parkin in the nucleus relative to cytoplasm (right panel) indicates
that parkin is excluded from the nucleus after SNOC exposure. Scale bar: 10 μm. Values are mean + SEM, n = 9 from triplicate experiments;
* p < 0.01. B, Chromatin immunoprecipitation (ChIP) assay using a specific parkin antibody (MAB5512) and oligonucleotide probe encoding the
human p53 promoter sequence. Control or parkin-overexpressing SH-SY5Y cells were exposed to 200 μM GSNO (or GSH) for 4 hours prior to
performing the ChIP assay. Relative fold enrichment was assessed and normalized to control. Values are mean + SEM, n = 4–5; * p < 0.05.
C, Electrophoretic mobility shift assay (EMSA) using recombinant parkin protein and oligonucleotide probe encoding the human p53 promoter
sequence. Parkin proteins were pre-exposed to 200 μM old or fresh SNOC prior to incubation with the oligonucleotide probe. The optical density
of shifted bands was quantified and expressed as percent control. Values are mean + SEM, n = 4; * p < 0.01.
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immunoblot analysis, transient expression of p53-shRNA
reduced endogenous p53 protein levels by 65% (Figure 4A).
Considering the fact that the transfection efficiency of
p53-shRNA was ~75%, we concluded that p53-shRNA
effectively knocked down endogenous p53.
Next, we transiently co-transfected SH-SY5Y cells with
an expression vector encoding parkin cDNA together
with the p53-shRNA vector (Figure 4B). As controls,
pcDNA and non-targeting control (ctrl-) shRNA vectors
were substituted for the parkin expression vector and
p53-shRNA vector, respectively. shRNA vectors also
encoded GFP to facilitate identification of transfected
cells. After transfection, we exposed the cells to 600 μM
SNOC for 24 hours and then evaluated cell death
by terminal-deoxynucleotidyl-transferase dUTP nick end
labeling (TUNEL) assay. We scored the number of
apoptotic cells as a percentage of total GFP-positive
cells (Figure 4C). Firstly, transfection with the parkin
plasmid reduced the number of apoptotic cells under all
conditions examined, indicating that parkin overexpression
was neuroprotective as expected based upon prior
reports. Secondly, in cells transfected with control
pcDNA, SNOC exposure induced apoptosis that wasnot inhibited by p53-shRNA transfection. In contrast,
cells overexpressing parkin manifested SNOC-induced
cell death that was significantly ameliorated by trans-
fection with p53-shRNA. These data are consistent
with the existence of a specific cell-death pathway in
neuronal cells in which S-nitrosylation of parkin inacti-
vates its neuroprotective function at least in part by
triggering p53-mediated apoptosis (Figure 4D).
Pesticide-induced apoptosis in parkin-overexpressing
SH-SY5Y neuroblastoma cells is mediated by p53
Subsequently, we studied the mechanism of cell death
induced by the herbicide paraquat (PQ) and fungicide
maneb (MB), the combination of which have been epide-
miologically linked to human Parkinson’s disease [27-29]
and are known to induce selective loss of dopaminergic
neurons in rodents [30-32]. Moreover, PQ and MB have
been extensively used in both in vitro and in vivo models
of Parkinson’s disease [30-34].
In the present study, we transiently transfected SH-
SY5Y cells with the parkin-expression vector together
with the GFP-p53-shRNA vector. As described previ-
ously, pcDNA and ctrl-shRNA vectors served as con-
trols. We then incubated the cells with 100 μM PQ and
Figure 4 Role of p53 in NO-induced death in SH-SY5Y cells overexpressing parkin. A, Validation of p53-shRNA as a gene-silencing tool. SH-
SY5Y cells were transfected with control (ctrl)- or p53 shRNA encoding plasmids, and the cell lysates subjected to western blotting using anti-p53
or actin antibodies. The optical density of the p53 bands was quantified and normalized to actin, n = 3; * p < 0.01. B, Histological images of SH-
SY5Y cells transiently transfected with pcDNA or parkin plasmid. Cells were co-transfected with ctrl- or p53-shRNA plasmids that also encoded
GFP (green). Cells were exposed to 600 μM old or fresh SNOC 24 h prior to TUNEL (red) staining. Scale bar: 20 μm. C, Percentage of TUNEL-
positive cells among GFP-positive cells under the designated conditions. Values are mean + SEM of 41–83 cells per condition performed in
triplicate experiments; * p < 0.05. D, Schematic representation of the pathway linking NO to apoptosis in this system.
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by TUNEL assay (Figure 5A). We then calculated the
number of apoptotic cells as a percentage of total GFP-
positive cells (Figure 5B).
The results obtained after exposure to PQ/MB were
similar to those obtained after exposure to SNOC. For
example, p53-shRNA did not attenuate cell death in
pcDNA-transfected cells after PQ/MB exposure. In con-
trast, in parkin-expressing cells, p53-shRNA abrogated
PQ/MB-induced cell death, with the number of apop-
totic cells returning to control values obtained in theabsence of PQ/MB exposure. In summary, both SNOC
and PQ/MB exposure triggered p53-dependent death in
cells that were transfected with parkin.
PQ/MB-induced neuronal cell death in primary
mesencephalic cultures is mediated by NO
We next studied the mechanism of PQ/MB-induced
cell death in mesencephalic primary cultures, as dopa-
minergic neurons in this area of the brainstem are spe-
cific targets of these pesticides in PD. For this purpose,
we prepared primary cultures of mesencephalon from
Figure 5 Role of p53 in herbicide/fungicide-induced apoptosis in SH-SY5Y cells overexpressing parkin. A, Histological images of cells
transiently co-transfected with plasmids for pcDNA or parkin, together with shRNA vectors coexpressing GFP (green). Cells were exposed to a
combination of 100 μM paraquat (PQ) and 10 μM maneb (MB) or vehicle for 6 h, fixed, and subjected to TUNEL staining (red). Scale bar: 20 μm.
B, Percentage of TUNEL-positive cells among GFP-positive cells under the indicated conditions. Values are mean + SEM of 183–656 cells per
condition performed in triplicate experiments; * p < 0.05.
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munocytochemistry and immunoblot analyses revealed
that mesencephalic cells positive for dopamine trans-
porters (DAT) also expressed parkin (Figure 6A,B). We
then exposed the cultured cells to 100 μM PQ and 10
μM MB for 6 hours in the presence or absence of 1 mM
of the broad spectrum NO synthase (NOS) inhibitor
NG-nitro-l-arginine (NNA), and found significantly in-
creased apoptotic death with PQ/MB that was inhibited
by NNA (Figure 6C). These results are consistent with
the notion that PQ/MB-induced cell death in the mesen-
cephalon is mediated predominantly by NO.
SNO-parkin, p53 levels, and neuronal damage are
increased in a mouse model of sporadic PD
We next asked whether parkin is S-nitrosylated in vivo
in animal models of PD induced by exposure to PQ/MB
in the presence or absence of the relatively neuronal
specific NOS inhibitor 3-bromo-7-nitroindazole (3-Br-7-
NI). Using the biotin-switch assay, we found a significant
increase in S-nitrosylation of parkin (represented bythe ratio of SNO-parkin/total parkin) in whole-brain
lysates of PQ/MB-exposed mice compared to control
brains (Figure 7). Moreover, SNO-parkin formation was
attenuated by treatment with 3-Br-7-NI, indicating that
endogenous NO was responsible for this nitrosylation
reaction. Concomitantly, p53 expression was increased
in PQ/MB-exposed animals compared to controls,
and 3-Br-7-NI significantly abrogated this increase in
p53 (Figure 7).
To determine the pathological consequences of the
PQ/MB-induced nitrosative stress, we performed im-
munohistological analyses on tissue samples prepared
from these mice. Tyrosine hydroxylase (TH) staining,
representing dopaminergic neurons, was increased in
the substantia nigra after 3-Br-7-NI treatment of PQ/
MB-injected mice (Figure 8). Similarly, immunohisto-
chemistry for the general neuronal markers NeuN and
MAP2 revealed that PQ/MB injection caused neuronal
loss in the basal ganglia and cerebral cortex, which was
rescued by 3-Br-7-NI (Figure 8). Additionally, we quanti-
fied proliferating cell nuclear antigen (PCNA) staining in
Figure 6 Role of NO in herbicide/fungicide-induced neuronal death in mesencephalic primary cultures. A, Histological images of
mesencephalic mixed cultures. Immunostaining for dopamine transporter (DAT, red), parkin (green), and Hoechst dye (blue). Scale bars: 20 μm.
B, Protein levels of parkin measured by western blot of cell lysates. C, Images of primary cultures exposed to a combination of 100 μM paraquat
(PQ) and 10 μM maneb (MB), with 1 mM Nω-nitro-L-arginine (NNA) or vehicle for 6 h. Staining for TUNEL (red) and Hoechst (blue). Scale bar: 10
μm. Quantification of the percentage of TUNEL-positive nuclei in each experimental condition shows PQ/MB induces cell death while NNA
inhibits PQ/MB-induced death. Values are mean + SEM of 100–341 nuclei per condition performed in triplicate experiments; * p < 0.05.
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sponsible for adult neurogenesis in the hippocampus; we
found that PCNA was significantly reduced after PQ/
MB injection, while 3-Br-7-NI treatment partially res-
cued this effect (Figure 8). Reduced proliferative capacity
in human PD brain has been reported previously, and
these agricultural chemicals can mimic this effect in
mouse PD models [35-37]. To our knowledge, however,
our new findings represent the first demonstration of
partial rescue of adult neural stem cell proliferation by
nNOS inhibition in a PD model caused by exposure to
these pesticides. Furthermore, injection of PQ/MB pro-
duced an increase in GFAP optical density in the cere-
bral cortex, hippocampus, and basal ganglia, consistent
with previous observations that a reactive astrocytosis
occurs in these rodents [30,32]; 3-Br-7-NI treatment
largely inhibited this effect as well (Figure 8). TakenFigure 7 Increased S-nitrosylation of parkin and p53 levels in a mous
parkin, p53, and actin were examined by biotin-switch and western blot in
3-Br-7-NI (left panel). Ratios of SNO-parkin and total parkin were quantified
conditions (center panel). Quantifications of p53 signal were normalized to
* p < 0.05.together, these results show that exposure to PQ/MB
in vivo leads to S-nitrosylation of parkin, accompanied
by increased p53 expression, astrocytosis, neuronal cell
loss and decreased proliferation of neural stem cells, and
that these adverse effects can be at least partially amelio-
rated by inhibition of nNOS.
Correlation of increased SNO-parkin and p53 protein
levels in human parkinsonian brains
Given the aforementioned results, we predicted that
human PD brain would exhibit increased levels of SNO-
parkin, which in turn would lead to increased p53
protein levels. To address this question, we obtained
postmortem brains of patients with PD and incidental
Lewy body disease (ILBD), along with unaffected control
brains (Table 1). All brains had relatively short postmor-
tem times and were flash frozen. We quantified thee model of PD. Levels of S-nitrosylated parkin (SNO-parkin), total
mice treated with the nNOS inhibitor 3-Br-7-NI, PQ/MB, or PQ/MB with
to indicate the extent of parkin S-nitrosylation under the indicated
actin (right panel). Values are mean + SEM, n = 3 mice per condition;
Figure 8 Dopamine synthesis, neuronal survival, neurogenesis and astrocytosis in a mouse model of PD. A, Histological images of brain
slices from mice treated with PQ/MB, the nNOS inhibitor 3-Br-7-NI, or PQ/MB with 3-Br-7-NI. Staining for TH, NeuN, MAP2, PCNA or GFAP are
shown in the indicated brain regions. Scale bars: 75 μm (TH), 35 μm (NeuN), and 25 μm (MAP2, PCNA, GFAP). B, Quantification of number of cells
staining for TH, NeuN and PCNA; quantitative confocal immunoreactivity for MAP2; and quantitative optical density for GFAP under the
conditions indicated in the specified brain regions. Values are mean + SEM, n = 5–6 mice per condition; * p < 0.05.
Table 1 Human brain samples
Conditions Lewy body
density score
Gender Age (years) PMI (hours)
ctrl - m 81 2.75
ctrl - m 82 3.66
PD 1 m 69 4.16
PD 1 f 82 3
PD 1 m 70 1.83
PD 1 f 73 2.16
PD 3 f 85 1.75
ILBD 1 m 91 3.33
ILBD 3 m 97 1.87
Posterior temporal cortical samples from unaffected control (ctrl), Parkinson’s
disease (PD) and Incidental Lewy body disease (ILBD) patients were analyzed.
Each patient’s clinical condition, Lewy body density score, gender (m = male,
f = female), age, and postmortem interval (PMI) are indicated.
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assay, and also total parkin and p53 protein levels by im-
munoblotting (Figure 9A). By quantitative densitometric
analysis, we found the ratio of SNO-parkin to total par-
kin was increased in human PD brains by 15-fold com-
pared to control levels (2.33 a.u. vs 0.15 a.u; Figure 9B).
In addition, we observed a consistent increase in p53
protein levels both in the brains of PD (1.39 a.u.) and
ILBD (1.53 a.u.) compared to controls (0.08 a.u.),
representing an increase of >15-fold in both disease
states (Figure 9C). Finally, the ratio of SNO-parkin to
total parkin was plotted against the p53 level for each
sample (Figure 9D), and these two values were found to
be highly correlated (Pearson correlation coefficient =
0.682). Taken together, both PD and ILBD human brains
exhibited an increased SNO-parkin/parkin ratio, accom-
panied by an increase in p53 levels.
Figure 9 Increased S-nitrosylation of parkin and p53 levels in
postmortem human brains from Parkinson’s disease (PD) and
Incidental Lewy body disease (ILBD). A, Levels of SNO-parkin, total
parkin, p53, and actin examined by biotin-switch and western blot in
lysates prepared from unaffected control brains (ctrl) and brains with
PD and ILBD. B, Ratios of SNO-parkin relative to total parkin were
calculated to indicate the extent of parkin S-nitrosylation in ctrl, PD and
ILBD samples. Values are mean + SEM of samples from 2 control, 5 PD
and 2 ILBD human brains; * p < 0.05. C, p53 levels are quantified and
normalized to actin for ctrl, PD and ILBD brains. Values are mean +
SEM; * p < 0.01. D, Ratios of SNO-parkin/parkin and p53/actin were
plotted for each sample. The two values are positively correlated with a
Pearson correlation coefficient of 0.682 and p < 0.05.
Sunico et al. Molecular Neurodegeneration 2013, 8:29 Page 9 of 16
http://www.molecularneurodegeneration.com/content/8/1/29Discussion
Previous reports had demonstrated a novel role of parkin
as a transcriptional repressor of the tumor suppressor gene
p53 [20]. In agreement with this observation, in the present
study we found that parkin represses p53 promoter activity
in cells expressing parkin either transiently or stably. In a
recent article, Duplan and colleagues identified a parkin
consensus binding sequence within the promoters of p53,
presenilin 1 and presenilin 2. This GCCGGAG heptamer
motif [38] is encompassed in the probes used in the EMSA
experiments in the current study. Moreover, we found that
the effect of parkin on p53 affects cell viability. Thus, the
neuroprotective action of parkin is at least in part mediated
by transcriptional suppression of p53, and this action ap-
pears to be independent of parkin’s ubiquitin E3 ligase ac-
tivity. Interestingly, recent studies also identified p53 as a
transcriptional activator of parkin in human lung and colon
cancer cell lines [39] as well as in gliomas [40]. However, in
human neuronal cells, p53 does not appear to control par-
kin expression, and thus negative feedback regulation be-
tween parkin and p53 may not occur in neurons.
In the present work, we explore the role of a posttransla-
tional modification, S-nitrosylation, on the neuroprotective
effect of parkin that is mediated via p53 suppression. Even
though exposure to NO donors can S-nitrosylate a numberof other proteins, we have been able to elucidate the role
of S-nitrosylated parkin by comparing results in cells with
and without exogenously-expressed parkin. We report evi-
dence that SNO-parkin attenuates the transcriptional re-
pression of p53, and thus S-nitrosylation of parkin induces
p53-mediated apoptosis in neuronal cells. Treatment with
NO donors not only causes misslocalization of parkin but
also inhibits the ability of parkin to bind to the p53 pro-
moter sequence, as evidenced by EMSA and ChIP experi-
ments. Therefore, it appears that the combination of these
two effects may contribute to the cell death induced by
parkin S-nitrosylation. Nonetheless, we do not rule out the
possibility that the E3 ubiquitin ligase activity of parkin is
also affected by nitrosative stress in PD, as indeed we and
others have previously suggested [24,26]. Human sporadic
PD has been epidemiologically linked to exposure to agri-
cultural pesticides, particularly the simultaneous use of PQ
and MB [4,5,27]. Our data support the notion that
pesticide-induced SNO modification of parkin may con-
tribute to ‘sporadic’ forms of PD, in a sense mimicking the
effects of genetic mutations of parkin. In this regard, it
should be noted that parkin-mediated control of p53 tran-
scription is abrogated by several mutations of parkin that
are known to cause familial PD [20]. In addition, S-
nitrosylation, as well as tyrosine phosphorylation, of parkin
have been reported to abolish its ubiquitin ligase activity in
sporadic forms of PD [9,12,16,24,26,41]. Taken together,
these data provide a unifying view of a mechanism under-
lying the pathogenesis of some forms of both sporadic and
familial PD; namely, posttranslational (or epigenetic) modi-
fications of parkin can cause partial or total loss of parkin
activity, mimicking the effects of genetic mutations.
Additionally, we found that inhibition of nNOS abated
the neuronal apoptosis observed in a rodent model of PD
induced by exposure to PQ/MB. We also demonstrate here
for the first time that inhibition of nNOS can ameliorate
PQ/MB-induced reduction in adult neural stem cell prolif-
eration. These findings are consistent with a role for NO in
these events. In corroboration of this conclusion, multiple
other studies have suggested the involvement of NO in the
apoptotic cell death of dopaminergic and other neurons
that occurs in PD [42-45]. Importantly, human postmor-
tem brain tissue from PD patients exhibit an upregulation
of NOS, reactive nitrogen species [46-48], and reactive oxy-
gen species [10,49]. Further, in several (but not all) reports,
NO inhibits adult neurogenesis in the dentate gyrus
[50,51], as observed here in PD mice produced by exposure
to PQ/MB. We also found that nitrosative stress induced
via pesticide exposure led to S-nitrosylation of parkin in
these mice, contributing to dysfunctional parkin activity.
Making these observations potentially relevant to the hu-
man condition, we and others have previously reported
that SNO-parkin levels are dramatically elevated in human
postmortem brains from sporadic PD patients [24,26].
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neural cells expressing parkin that NO-induced death is
dependent on p53. While several studies have connected
nitrosative stress with p53 accumulation [52-55], S-
nitrosylation of p53 does not seem to affect p53 binding to
DNA [56]. In several experimental PD model systems,
phosphorylation is known to activate p53 in neurons that
subsequently undergo apoptosis [57-59]. Other reports
have suggested a link between NO-induced processes, p53
activity and neuronal cell death, albeit the involvement of
parkin was not yet known [60]. Moreover, in a number
of PD model systems, inhibition of p53 has been shown
to protect dopaminergic neurons and motor function
[61,62], as well as increase adult neural stem cell prolifera-
tion [63]. Taken together with prior reports, our findings
support the notion that p53 is a downstream effector of
parkin, in part responsible for the pathogenesis of PD. Im-
portantly, we demonstrate that S-nitrosylation of parkin
leads to pathological activation of the p53 gene, thus con-
tributing to this pathogenic mechanism.
In support of this conclusion, we found in both a mur-
ine model of pesticide-induced ‘sporadic’ PD and in hu-
man cases of sporadic PD that the brain exhibits not
only elevated SNO-parkin but also an increase in p53
protein levels, which is accompanied by neuronal cell
loss. While prior reports had noted increased levels of
p53 in human PD brain [20,64,65], in the present study,
we also found a striking positive correlation between
parkin S-nitrosylation and p53 protein levels, thus
supporting a possible link between these two events.
In summary, parkin is a neuroprotective molecule that
binds to the promoter region of the p53 gene, thus sup-
pressing its activity under physiological conditions. In
the present work we propose that in the presence of pes-
ticides or other forms of environmental stress leading to
the excessive generation of NO, parkin becomes S-
nitrosylated. SNO-parkin, in turn, is excluded from the
nucleus and loses its ability to bind to the p53 promoter
sequence (Figure 10). This leads to relative activation of
the p53 gene and increased levels of p53 protein, hence
contributing to apoptotic cell death in affected neurons.
Conclusions
In the present study, we show that S-nitrosylation of par-
kin leads to transcriptional activation of the p53 gene. This
reaction may underlie, at least in part, the pathogenesis of
sporadic PD. The discovery of this pathway affords an op-
portunity for developing novel therapeutics for PD.
Methods
Cell cultures, transfections and treatments
HEK-293 and SH-SY5Y cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Sigma) supplemented
with 10% of heat-inactivated fetal bovine serum (FBS,HyClone), 2 mM L-glutamine (Gibco-Invitrogen), 50
IU/ml penicillin (Omega Scientific) and 50 μg/ml
streptomycin (Omega Scientific). Cells were cultured in
100 mm culture plates at 37°C in a water-saturated at-
mosphere of 95% air and 5% CO2. The SH-SY5Y cell
line stably overexpressing parkin (Parkin-SY5Y cells)
was prepared by selecting the transfectants with
geneticin (Gibco-Invitrogen). Parkin-SY5Y cells were
maintained in DMEM supplemented with 10% FBS, 2
mM l-glutamine, 50 IU/ml penicillin, 50 μg/ml strepto-
mycin and 100 μg/ml geneticin. Transfections were
performed in 6-well plates using Lipofectamine LTX
and Plus Reagent (Invitrogen) according to the manu-
facturer’s instructions.
Cultures of neuroblastoma cell lines were grown in 6-
well plates. When indicated, cells were exposed for 6–24
hours with 200–600 μM of the short-half life nitric oxide
donor S-nitrosocysteine (SNOC), or control solution from
which NO had been previously dissipated (designated ‘old’
SNOC). Additional exposures included 200 μM of the
long-half life NO donor S-nitrosoglutathione (GSNO) or
glutathione (GSH) as its negative control. The neuro-
blastoma cell line and mesencephalic primary cultures
containing substantia nigra cells were exposed to pesti-
cides previously linked to PD in epidemiological studies,
including 100 μM of the herbicide paraquat (PQ; Fluka)
and 10 μM of the fungicide maneb (MB; Fluka). These
concentrations were chosen as approximately two-fold the
maximal allowed exposure level from EPA data (US EPA
codes CASRN 1910-42-5 and CASRN 12427-38-2, re-
spectively). In some cases, 1 mM of the broad spectrum
NOS inhibitor NG-nitro-L-Arginine (NNA; Alexis) was
added. Cells were exposed for 6 hours at 37°C in a water-
saturated atmosphere of 95% air and 5% CO2. Recombin-
ant proteins were exposed to 200 μM SNOC or old SNOC
for 10 min at room temperature.
Primary mesencephalic cultures
Mixed mesencephalic primary cultures, including substantia
nigra, were prepared from embryonic day-13 (E13) fe-
tuses of Sprague–Dawley rats. The mesencephalon was
dissected in ice-cold EBSS (Gibco-Invitrogen) and sub-
sequently digested in 0.25% trypsin (Gibco-Invitrogen)
for 35 minutes at 37°C in a 7% CO2 humidified incuba-
tor. Tissues were washed with pre-incubation medium
containing DMEM Ham’s F-12 (1:1) (Omega Scientific),
10% fetal bovine serum (FBS, HyClone), 50 IU/ml peni-
cillin (Omega Scientific) and 50 μg/ml streptomycin
(Omega Scientific) and dissociated by trituration. Cells
were plated on 24-well plates coated with poly-l-lysine
(Sigma) in 1:1 pre-incubation medium combined with
incubation medium, the latter containing DMEM Ham’s
F-12, 0.5 mM l-glutamine (Gibco-Invitrogen), 1% B27
(Gibco-Invitrogen), 50 IU/ml penicillin and 50 μg/ml
Figure 10 Schematic representation of proposed mechanism whereby S-nitrosylation of parkin regulates p53-mediated neuronal
death in sporadic PD. A, Under physiological conditions, parkin is neuroprotective by repressing p53 transcription. B, During nitrosative stress,
for example due to pesticide exposure, parkin becomes S-nitrosylated. SNO-parkin no longer binds to the p53 promoter and is excluded from the
nucleus. This results in activation of the p53 gene and subsequent p53-mediated neuronal death.
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midified incubator; 24 hours after plating, the entire
medium was replaced with incubation medium. Subse-
quently, half of the incubation medium was replaced once
every four days. At 21 days in vitro (DIV), cells were fixed
with 4% paraformaldehyde or treated according to the spe-
cific experimental design. The percentage of dopaminergic
neurons in the mixed mesencephalic primary culture was
35 ± 4.5%, as measured by immunocytochemistry for the
dopamine transporter.
Human brain tissue
Human brain tissues were provided by the Banner Sun
Health Research Institute Brain and Body Donation Pro-
gram. All sample groups correspond to the posterior
temporal cortex, from the middle temporal gyrus at the
coronal level of the end of the lateral fissure. Samples
were frozen (−80°C) within less than 5 hours postmor-
tem (Table 1) and homogenized with HENTS buffer, pH
7.2 (100 mM Hepes, 1 mM EDTA, 0.1 mM neocuproine,
1% Triton X-100, 0.1% sodium dodecyl sulfate) prior to
biochemical analysis. The “control” group included sam-
ples from elderly patients with no history of dementia orother neurological diseases (Table 1). The “Parkinson’s
disease” (PD) group included samples from 5 different
brains obtained from patients whose clinical diagnosis in
life was verified at postmortem examination (males and
females, 69–85 years old; Table 1). The “incidental Lewy
body disease” (ILBD) group included samples from 2
clinically normal individuals but whose autopsy revealed
the presence of Lewy bodies in the central nervous sys-
tem by means of α-synuclein immunohistochemistry
(males, 91–97 years old; Table 1).
Mouse model of sporadic PD from pesticide exposure
Animal care was conducted in accordance with the
United States Public Health Service Guide for the Care
and Use of the Laboratory Animals, and all experiments
were approved by the University of California San Diego
Institutional Animal Care and Use Committee. Exposure
to the combination of pesticides paraquat (PQ) and
maneb (MB) has been linked to sporadic cases of human
PD in epidemiological studies [27-29] and can produce
selective loss of nigrostriatal dopaminergic cell bodies
and reduction in dopamine levels in the rodent striatum;
the combination of paraquat and maneb has therefore
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pesticides in rodents [30-33,66]. Female mice weighing
20–30 g were injected intraperitoneally (i.p.) with freshly
prepared paraquat (Fluka; 5 mg/kg) and maneb (Fluka;
15 mg/kg) twice a week for four weeks. Additional
groups of animals also received the relatively specific
neuronal NOS inhibitor 3-bromo-7-nitroindazole (3-Br-
7-NI, Enzo Life Sciences; 30 mg/kg) or vehicle (60%
DMSO in PBS) twice a week on alternate days for four
weeks. Animals were sacrificed after treatment. Half of
each brain was frozen at −80°C) and homogenized in
HENTS buffer prior to biochemical analysis. The re-
maining halves were fixed in 4% paraformaldehyde for
histological assessment of neuronal damage.
Postmortem processing and immunohistochemistry
To evaluate the neurodegenerative histological alterations
after pesticide exposure, blind-coded 40-μm thick vib-
ratome sections from mouse brains fixed in 4% parafor-
maldehyde were immunolabeled for different markers. To
assess the integrity of the dendritic system, sections were
immunolabeled with the mouse monoclonal antibody
against the dendritic marker microtubule-associated
protein 2 (MAP2; 1:40; Chemicon, Temecula, CA), as
previously described [67]. To evaluate neuronal damage,
blind-coded sections were immunolabeled with mouse
monoclonal antibody against the neuronal marker NeuN
(1:500; Millipore, Billerica, MA). To assess astroglial re-
sponse, tissue was incubated with the astroglial marker
glial fibrillary acidic protein (GFAP; 1:500; Dako, Fort
Collins, CO), as previously described [62,67]. For the
evaluation of dopamine synthesis, sections were incu-
bated with mouse anti-TH antibody (1:1000; Pel-Freez).
To assess proliferation capacity of adult stem cells that
are critical for neurogenesis, tissue was pre-treated with
formamide and HCl to denature DNA. Blind-coded sec-
tions were then immunolabeled with mouse monoclonal
antibody against PCNA (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA).
After overnight incubation with the specific primary anti-
body, for the detection of MAP2, sections were incubated
with FITC-conjugated horse anti-mouse IgG secondary
antibody (1:75, Vector Laboratories, Burlingame, CA),
transferred to SuperFrost slides (Fisher Scientific, Tustin,
CA) and mounted under glass coverslips with anti-fading
media (Vector). The immunolabeled blind-coded sections
were imaged with the laser scanning confocal microscope
(MRC1024, Bio-Rad, Hercules, CA) and analyzed with the
Image 1.43 program (NIH), as previously described [33,59].
For the detection of TH, NeuN, PCNA and GFAP, sections
were incubated with biotinylated secondary antibody and
avidin-conjugated peroxidase (both Vector). Staining was
visualized by incubating in diaminobenzidine solution
according to the manufacture’s directions (all from VectorLaboratories, Burlingame, CA) and analyzed with the
Quantimet 570C densitometer [33].
All sections were processed under the same standard-
ized conditions. For each mouse, a total of 3 sections
were analyzed and for each section, 4 fields in the spe-
cific brain region were examined. Results for all images
were averaged and expressed as the percentage area cov-
ered by immunoreactive dendrites in the case of MAP2,
as number of positive neurons per square millimeter in
the case of TH, NeuN and PCNA, and as corrected op-
tical density in the case of GFAP.
Luciferase reporter gene activity assay
Cells were seeded in 6-well plates, allowed to adhere
overnight, and then co-transfected in each well with 1.5
μg of p53-responsive luciferase reporter plasmid DNA
(kindly donated by Dr. Stephen H. Safe, Department of
Veterinary Physiology and Pharmacology at Texas A&M
University) and 0.5 μg of Renilla luciferase cDNA; in
some experiments1 μg of wild-type human parkin cDNA
construct was also transfected. The total amount of plas-
mid DNA per transfection was kept constant (3 μg per
well) by balancing the total transfected DNA amount
with empty vector pcDNA3 (Invitrogen). After incuba-
tion for 48 hours, cells were exposed to various proto-
cols, according to the specific experimental design.
Approximately 72 hours after transfection, cells were
lysed in 1x reporter lysis buffer (Promega), 20 μl of cell
extract was placed in each well of a 96-well plate, and
firefly and Renilla luciferase activity were measured in a
luminometer with a dual-luciferase reporter assay system
following the manufacturer’s instructions (Promega).
Firefly luminescence was normalized to the Renilla lumi-
nescence signal.
Protein extraction and western blot analyses
Cultured cells were harvested and lysed in RIPA buffer
(50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% Nonidet
P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sul-
phate) for 10 min at 4°C. Protein concentrations were
determined using the Bio-Rad protein assay dye ac-
cording to the manufacturer’s specifications. For im-
munoblotting, typically 5–30 μg of proteins were
resolved on 4-12% polyacrylamide NuPAGE-MES gels
(Invitrogen) and then wet-transferred to PVDF mem-
branes (Millipore). Membranes were blocked in 2%
skim milk in Tris-buffered saline (TBS) containing 1%
Tween-20 (TBS-T). Immunoblotting was performed
using mouse anti-parkin monoclonal antibody (1:1,000;
MAB5512, Millipore), rabbit anti-p53 polyclonal anti-
body (1:1,000; 9282, Cell Signaling), mouse anti-p53
monoclonal antibody (1:1,000; SC-99, Santa Cruz), mouse
monoclonal anti-β-actin antibody (1:5,000; MAB1501,
Millipore), or rabbit polyclonal anti-β-actin antibody
Sunico et al. Molecular Neurodegeneration 2013, 8:29 Page 13 of 16
http://www.molecularneurodegeneration.com/content/8/1/29(1:5,000; 4967, Cell Signaling) for mouse samples. For
cell line experiments, immunological complexes were
detected with goat anti-mouse (1:3,000; Jackson) or
goat anti-rabbit (1:3,000; BioRad) IgG secondary anti-
bodies coupled to peroxidase, followed by electro-
chemiluminescence using the Super Signal substrate kit
(Thermo Scientific) as directed by the manufacturer.
For human and mouse brain lysates, goat anti-mouse at
680 LT (1:20,000; Li-Cor) or goat anti-rabbit at 800
CW (1:15,000; Li-Cor) IR-dye-conjugated secondary
antibodies were used, followed by infrared analysis with
Odyssey (Li-Cor). When p53 was analysed in the hu-
man neuroblastoma cell line, polyclonal antibody anti-
p53 was used. In human and mouse brain samples, p53
was detected using the monoclonal antibody SC-99
(Santa Cruz).
Densitometric analysis of protein bands was performed
using Adobe Photoshop. All values were normalized to
their respective loading controls.
Biotin-switch assay for detection of S-nitrosylated
proteins
Analysis of S-nitrosylated parkin (SNO-parkin) with the
biotin-switch assay was performed as previously de-
scribed [26,68,69]. Briefly, fresh brain tissue samples
were homogenized in HEN buffer, pH 7.2 (100 mM
Hepes, 1 mM EDTA, 0.1 mM neocuproine) with 1% Tri-
ton X-100 and 0.1% sodium dodecyl sulfate. A total of 1
mg of protein per sample was used for the assay. Free
thiol groups were blocked by incubation with 20 mM
methyl methanethiol-sulfonate (MMTS; Aldrich) for 30
min at 50°C. Cell extracts were then precipitated with
acetone and resuspended in HEN buffer with 1% SDS.
S-Nitrosothiol groups were then selectively reduced by
75 mM ascorbate to free thiols, which were subsequently
biotinylated with 4 mM N-[6-(biotinamido)hexyl]-3′-
(2′-pyridyldithio)-propionamide (biotin-HPDP; Soltec
Ventures). The biotinylated proteins were pulled down
with streptavidin-agarose beads and analyzed by im-
munoblotting. Total protein as a loading control was
quantified by standard immunoblot analysis. Results
were expressed as SNO-parkin relative to total parkin
for each sample.
Immunocytochemistry and nuclear staining
Cell cultures were fixed in 4% paraformaldehyde in PBS
for 10 min, and then permeabilized with 0.1% Triton X-
100 and blocked with 5% goat serum for 30 min. Mouse
anti-myc (46–0603, Invitrogen), mouse anti-parkin (MA
B5512, Millipore) or rat anti-dopamine transporter
(AB5990, Abcam) monoclonal antibodies were used at
1:500 dilution (4°C overnight incubation). Goat anti-
mouse FITC- (115-095-166, Jackson ImmunoResearch) or
goat anti-rat rhodamine red-conjugated (112-295-075,Jackson ImmunoResearch) secondary antibodies were
used for fluorescence labeling at a dilution of 1:500 (RT, 1
hour). Nuclei were detected by co-staining with 12 μM
Hoechst 33342 (Molecular Probes) for 30 min. Coverslips
were mounted for immunofluorescence analysis using
Fluoro Gel mounting medium (Electron Microscopy Sci-
ences), and analysis of samples was performed on a decon-
volution epifluorescence microscope (Axio, Carl Zeiss
Microimaging GmbH).
Terminal-deoxynucleotidyl-transferase dUTP nick end
labeling (TUNEL) assay
For neuroblastoma cultures, cells were collected and
TUNEL assay was performed in suspension. For primary
neuronal cultures, TUNEL assay was performed on cov-
erslips. Briefly, cells were fixed with 4% paraformalde-
hyde in PBS for 10 min, and then permeabilized with
0.1% Triton X-100 and 0.1% sodium citrate for 2 min.
Apoptotic cells were labeled using an in situ cell death
detection kit (Roche) according to the manufacturer’s
instructions. Coverslips were mounted using Fluoro
Gel mounting medium, and apoptotic cells were ob-
served and quantified on a deconvolution epifluores-
cence microscope.
RNAi-mediated knockdown of p53
psiRNA vector expressing short hairpin RNA for effi-
ciently targeting and silencing human p53 gene (shRNA-
p53) was purchased from InvivoGen (psirna42-hp53).
Briefly, shRNA-p53 was produced with the psiRNA-
h7SKGFPzeo plasmid from the human 7SK RNA pol III
promoter, featuring a GFP-Zeo fusion gene for monitor-
ing transfection efficiency. psiRNA plasmid targeting
luciferase-GL3, whose sequence was not found in the
mouse, human or rat genome databases [70,71], was
used as a non-targeting control (shRNA-ctrl; InvivoGen).
shRNA vectors were amplified in competent E. coli
GT116 cells according to the manufacturer’s instruc-
tions. Transfection of neuroblastoma cells with shRNAs
was performed in 6-well plates using Lipofectamine LTX
and Plus Reagent (Invitrogen). A total of 3 μg of plasmid
DNA per well was used for each transfection.
Recombinant protein expression and purification
Recombinant GST-tagged parkin protein was expressed
and purified as previously described [26].
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the ChIP-IT EXPRESS
assay kit protocol (Active Motif, USA). Briefly, 1 × 107
SH-SY5Y cells that had been transfected with pcDNA or
parkin were exposed to 200 μM GSNO or GSH (as a con-
trol) for 4 hours. Cells were then cross-linked with 1% for-
maldehyde at room temperature for 10 min, washed with
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nuclear pellet was resuspended in shearing buffer and
sonicated with 8 pulses of 20 s each to shear DNA into
200–1000 bp fragments. Ten percent of the mixture
containing protein/DNA complexes was used for “input
DNA” analysis. An equal amount of the protein/DNA
complex mixture was then incubated at 4°C overnight
with magnetic beads and control IgG or an anti-parkin
antibody (MAB5512, Chemicon International, USA).
Immunoprecipitated DNA was then eluted from the
magnetic beads and the cross-linking was reversed. In-
put and ChIP DNA were analyzed using quantitative
real-time PCR. The human p53 promoter region was
amplified using forward primer 5′-CTCCAAAATGA
TTTCCACCAA-3′ and reverse primer 5′-GGAAGCA
AAGGAAATGGAGTT-3′ for determination of parkin
binding. For quantitative ChIP, the PCR was performed
using EXPRESS SYBR GreenERTM (Invitrogen, USA)
on the Stratagene Mx3000P Q-PCR system. Levels of
enrichment (n-fold) were calculated using the compara-
tive cycle threshold method.
Electrophoretic mobility shift assay (EMSA)
A synthetic oligonucleotide covering the region of the hu-
man p53 promoter (Pp53 forward and reverse; see below)
[20] labeled with biotin at the 5′ end was obtained from
IDT Integrated DNA Technologies and subsequently
annealed. For detection of binding of parkin to p53, 1 μM
recombinant, wild-type parkin was incubated with 0.1 nM
biotin-labeled DNA oligonucleotide. The specificity of the
reaction was verified by incubation of Pp53 with increasing
concentrations of recombinant parkin, typically from 100
nM to 1 μM. Binding reactions were performed at
room temperature for 20 min in 1x binding buffer
(Panomics). Then, protein-DNA complexes were re-
solved by electrophoresis on 6% polyacrylamide Novex
DNA retardation gels (Invitrogen) at 100 V in 0.5x TBE
buffer, pH 8.3 (90 mM Tris–HCl, 90 mM boric acid, 2
mM EDTA), and wet-transferred to biodyne B nylon
membranes (Pall Life Sciences). Oligonucleotides were
fixed to the membrane by UV crosslinking at 254 nm
for 5 min. After blocking the membrane with 1x
blocking buffer (Thermo Scientific), biotinylated oligo-
nucleotides were detected by incubation with stabilized
streptavidin-horseradish peroxidise conjugate (Thermo
Scientific), followed by electrochemiluminescence ana-
lysis using a substrate kit (Thermo Scientific) as di-







Data were quantified and stored in Excel software for-
mat (Microsoft, Redmond, WA). Graphs depicting data
from quantitative analyses were generated with PRISM
software (GraphPad Software). All experimental points
are expressed as mean ± SEM. Statistical differences
among different groups were determined by Student’s
t-test (for single comparisons) or ANOVA (for multiple
comparisons) using PRISM software.
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